ZEB1 throttles therapeutic target

ZEB1 throttles therapeutic target, protecting KRAS-mutant lung cancer

Don Gibbons

Protein forces a shift in cell type, a plasticity that promotes resistance to targeted therapy A cellular identity switch protects a cancer-promoting genetic pathway from targeted therapy, researchers at The University of Texas MD Anderson Cancer Center today reported in Science Translational Medicine. Working in cell lines and mouse models of lung cancer, a team led by Don Gibbons, M.D., Ph.D., associate professor of Thoracic/Head & Neck Medical Oncology, demonstrated how the KRAS-driven lung cancer cells defeat treatment by switching from stable, […]